▲ Peaking
Business
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
2sources
2articles
1velocity
+184%since first seen
1h agofirst detected
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Coverage (2)
- AstraZeneca shares down as drug trial fails to meet target The Times · 15h ago
- Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump Investor's Business Daily · 15h ago
Related trends
▲ Peaking
Business
Nasdaq ends sharply higher; chip surge offsets Iran worries
▲ Peaking
Business
Rumors of the DOOM studio's demise are being wildly exaggerated
▲ Peaking
Business
Delta expects higher airfare to last, bringing 2026 profit goal in reach, CEO says
Delta Airlines is leveraging strong travel demand and higher airfares to pursue its 2026 profit goals despite rising fuel costs.
▲ Peaking
Business
Xbox Layoffs Reduce id Tech Engine Team to 1 Developer, As Unreal Engine Dominance Is Set To Grip The Industry
▲ Peaking
Business
Instagram’s AI image generator alarms privacy experts
▲ Peaking
Business
Here's How Much More Upside Is Left in Palantir Stock, According to Wall Street Analysts
Wall Street analysts are weighing Palantir's valuation and future upside following a 25% rally in the stock.